Itraconazole Increases Ibrutinib Exposure 10‐Fold and Reduces Interindividual Variation—A Potentially Beneficial Drug‐Drug Interaction

Bibliographic Details
Title: Itraconazole Increases Ibrutinib Exposure 10‐Fold and Reduces Interindividual Variation—A Potentially Beneficial Drug‐Drug Interaction
Authors: Tuija Tapaninen, Aleksi M. Olkkola, Aleksi Tornio, Mikko Neuvonen, Erkki Elonen, Pertti J. Neuvonen, Mikko Niemi, Janne T. Backman
Source: Clinical and Translational Science, Vol 13, Iss 2, Pp 345-351 (2020)
Publisher Information: Wiley, 2020.
Publication Year: 2020
Collection: LCC:Therapeutics. Pharmacology
LCC:Public aspects of medicine
Subject Terms: Therapeutics. Pharmacology, RM1-950, Public aspects of medicine, RA1-1270
More Details: The oral bioavailability of ibrutinib is low and variable, mainly due to extensive first‐pass metabolism by cytochrome P450 (CYP) 3A4. The unpredictable exposure can compromise its safe and effective dosing. We examined the impact of itraconazole on ibrutinib pharmacokinetics. In a randomized crossover study, 11 healthy subjects were administered itraconazole 200 mg or placebo twice on day 1, and once on days 2–4. On day 3, 1 hour after itraconazole (placebo) and breakfast, ibrutinib (140 mg during placebo; 15 mg during itraconazole) was administered. Itraconazole increased the dose‐adjusted geometric mean area under the concentration‐time curve from zero to infinity (AUC0–∞) of ibrutinib 10.0‐fold (90% confidence interval (CI) 7.2–13.9; P
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1752-8062
1752-8054
Relation: https://doaj.org/toc/1752-8054; https://doaj.org/toc/1752-8062
DOI: 10.1111/cts.12716
Access URL: https://doaj.org/article/701e1cf86da34400937cd534eb0f5ba8
Accession Number: edsdoj.701e1cf86da34400937cd534eb0f5ba8
Database: Directory of Open Access Journals
Full text is not displayed to guests.
More Details
ISSN:17528062
17528054
DOI:10.1111/cts.12716
Published in:Clinical and Translational Science
Language:English